
|Articles|March 12, 2014
- Immunotherapy (Issue 2)
- Volume 2
- Issue 1
How Immunotherapies are Changing the Treatment of Melanoma
Author(s)Harriet Kluger, MD
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Advertisement
Harriet Kluger, MD, associate professor of medicine (medical oncology), associate director, Hematology/Oncology Fellowship Program, Yale Cancer Center, explains how immunotherapies are changing the treatment of melanoma.
Read more about ipilimumab, nivolumab, and other immunotherapies being looked at in melanoma > >
Articles in this issue
about 12 years ago
The Outlook for CAR-Modified T Cellsabout 12 years ago
B-Cell Malignancies Faring Well With Immunotherapiesabout 12 years ago
Update on Immunotherapy and Targeted Combination Therapiesabout 12 years ago
Progress Made With PD-L1 as Predictive Biomarkerabout 12 years ago
Oncolytic Viral Therapies About to Spreadabout 12 years ago
The Future of Immunotherapy Treatments in Lung Cancerabout 12 years ago
Checking in on Checkpoint InhibitorsAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
3
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































